Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290
NN7415-4616
Phase 3 small_molecule active
Quick answer
Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290 for Haemophilia A or B with or without inhibitors is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Haemophilia A or B with or without inhibitors
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active